U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07017270) titled 'Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis' on April 24.
Brief Summary: This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Kidney Disease, Chronic
Diabetes
Dialysis
End Stage Kidney Disease (ESRD)
Intervention:
DRUG: Semaglutide Pen
Individuals randomized ...